The Optimization of Bioavailability From Iron Supplements: Study 2

Anemia Clinical Trial

Official title:

The Optimization of Bioavailability From Iron Supplements: Examinations of Different Supplementation Regimens Including Hepcidin Profiles

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02177851
• Other study ID #: FeSupp_Hep-2
• Status: Completed
• Phase: N/A
• First received: June 25, 2014
• Last updated: January 20, 2016
• Start date: June 2015
• Est. completion date: December 2015

Study information

• Verified date: September 2015
• Source: Swiss Federal Institute of Technology
• Contact: n/a
• Is FDA regulated: No
• Health authority: Switzerland: Cantonal ethic committee of Zurich
• Study type: Interventional

Clinical Trial Summary

Iron deficiency (ID) with or without anaemia (IDA) is a major public health problem worldwide, especially in women of reproductive age and young children. Iron supplementation is an effective strategy to prevent and treat ID and IDA. There is a lack of data on iron bioavailability from different supplementation regimens and how to optimize bioavailability in a cost-effective and patient-friendly way. The daily supplementation with 1-4 mg Fe/kg body weight for 3 months is reported to be the most effective method to rapidly increase iron stores in subjects with ID and IDA. In IDA patients, medical practitioners often prescribe supplementation regimens with 120 mg iron per day split into 2 doses with 60 mg iron, arguing that the splitting would increase iron bioavailability compared with one single high dose. However, there is no scientific evidence for this assumption; to the contrary, results from a recent study suggest that iron bioavailability from a second supplementation dose of iron after a first supplementation dose of iron is impaired due to increased hepcidin levels. To address this bioavailability issue, the present study will determine iron absorption from 120 mg iron administered for 3 consecutive days and compare it with that from 2 doses of 60 mg iron per day administered for 3 consecutive days. The investigators hypothesize that the iron bioavailability from the single daily dose will be lower than that from the 2 doses. By measuring also hepcidin, this study will provide important insights on the iron bioavailability from a single dose of iron and on the same amount iron split into two doses (b.i.d. administration).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 20
• Est. completion date: December 2015
• Est. primary completion date: September 2015
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 18 Years to 45 Years

Eligibility

Inclusion Criteria:

• Female, 18 to 45 years old,

• Serum Ferritin levels <20 µg/L,

• Normal body Mass Index (18.5-25 kg/m2),

• Body weight <65 kg,

• Signed informed consent

Exclusion Criteria:

• Anaemia (Hb < 11.7 g/dL),

• Elevated c-reactive protein or alpha1 glycoprotein concentrations >5.0 mg/L, >1.0 g/L, respectively,

• Any metabolic, gastrointestinal kidney or chronic disease such as diabetes, renal failure, hepatic dysfunction, hepatitis, hypertension, cancer or cardiovascular diseases (according to the participants own statement),

• Continuous/long-term use of medication during the whole studies (except for contraceptives),

• Consumption of mineral and vitamin supplements within 2 weeks prior to 1st supplement administration,

• Blood transfusion, blood donation or significant blood loss (accident, surgery) over the past 4 months,

• Earlier participation in a study using stable iron isotopes,

• Known hypersensitivity or allergy to iron supplements,

• Women who are pregnant or breast feeding,

• Intention to become pregnant during the course of the studies,

• Lack of safe contraception, defined as: Female participants of childbearing potential, not using and not willing to continue using a medically reliable method of contraception for the entire study duration, such as oral, injectable, or implantable contraceptives, or intrauterine contraceptive devices, or who are not using any other method considered sufficiently reliable by the investigator in individual cases.

• Known or suspected non-compliance, drug or alcohol abuse,

• Inability to follow the procedures of the studies, e.g. due to language problems, psychological disorders, dementia, etc. of the participant,

• Participation in another study with investigational drug within the 30 days preceding and during the present studies,

• Enrolment of the investigator, his/her family members, employees and other dependent persons

Study Design

Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention

Related Conditions & MeSH terms

• Anemia
• Anemia, Iron-Deficiency
• Iron Deficiency
• Iron Deficiency Anemia

Intervention

Dietary Supplement:
• Single oral iron dose of 120 mg per day for 3 consecutive days

• Two oral iron doses of 60 mg per day (morning + afternoon) for 3 consecutive days

Locations

Country	Name	City	State
Switzerland	Human Nutrition Laboratory	Zurich

Sponsors (1)

Lead Sponsor	Collaborator
Swiss Federal Institute of Technology

Country where clinical trial is conducted

Switzerland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Iron bio-availability (%) from oral iron supplementation (3x 120 mg)	Iron bioavailability will be assessed with stable isotopic labels. The shift in the isotopic ratio in human whole blood will be measured with Inductively coupled plasma mass spectrometry (ICP-MS).	3 days	No
Primary	Serum hepcidin concentrations on the 1st day of iron supplementation		1 day	No
Primary	Iron bio-availability (%) from oral iron supplementation (6x 60 mg)	Iron bioavailability will be assessed with stable isotopic labels. The shift in the isotopic ratio in human whole blood will be measured with Inductively coupled plasma mass spectrometry (ICP-MS).	6 days	No
Primary	Serum hepcidin concentrations on the 2nd day of iron supplementation		2 days	No
Primary	Serum hepcidin concentrations on the 3rd day of iron supplementation		3 days	No
Primary	Serum hepcidin concentrations on the 4th day of iron supplementation		4 days	No
Primary	Serum hepcidin concentrations on the 5th day of iron supplementation		5 days	No
Primary	Serum hepcidin concentrations on the 6th day of iron supplementation		6 days	No